Monitoring the randomized trials of the Women's Health Initiative: The experience of the Data and Safety Monitoring Board

Clinical Trials

Volumn 4, Issue 3, 2007, Pages 218-234

  Wittes, Janet ^a   Barrett Connor, Elizabeth ^b   Braunwald, Eugene ^c   Chesney, Margaret ^d   Cohen, Harvey Jay ^e   DeMets, David ^f   Dunn, Leo ^g   Dwyer, Johanna ^h   Heaney, Robert P ⁱ   Vogel, Victor ^j   Walters, LeRoy ^k   Yusuf, Salim ^l  

^a University of Iowa   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d National Institutes of Health   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ CREIGHTON UNIVERSITY   (United States)

^j UNIVERSITY OF PITTSBURGH   (United States)

^k GEORGETOWN UNIVERSITY   (United States)

^l MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; VITAMIN D;

ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DIET SUPPLEMENTATION; HEART INFARCTION; HORMONAL THERAPY; HUMAN; LUNG EMBOLISM; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; STROKE; TREATMENT INDICATION; WOMEN'S HEALTH;

CALCIUM; CARDIOVASCULAR DISEASES; CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA INTERPRETATION, STATISTICAL; DIETARY SUPPLEMENTS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; PROGESTERONE CONGENERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; VITAMIN D; WOMEN'S HEALTH;

EID: 34548616370     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1191/1740774507079439     Document Type: Article

References (22)

1. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998; 19: 61-109.
2. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
3. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
4. Prentice RL, Caan B, Chlebowski R et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative randomized controlled dietary modification trial. JAMA 2006; 295: 629-42.
5. Beresford SAA, Johnson KC, Ritenbaugh C et al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative randomized controlled dietary modification trial. JAMA 2006; 295: 643-54.
6. Jackson RD, LaCroix AZ, Gass M et al. The Women's Health Initiative trial of calcium plus vitamin D supplementation on risk for fractures. N Engl J Med 2006; 354: 669-83.
7. Thaul S, Hotra D eds. An assessment of the NIH Women's Health Initiative. National Academy of Science Press, 1993: 160pp.
8. Freedman LS, Anderson G, Kipnis V et al. Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. Control Clin Trials 1996; 17: 509-25.
9. Skali H, Pfeffer M, Lubsen J et al. Variable impact of combining fatal and nonfatal end points in heart failure trials. Circulation 2006; 114: 2298-303.
10. Canner P. Monitoring of the data for evidence of adverse or beneficial treatment effects. Control Clin Trials 1983; 4: 467-83.
11. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group, JAMA 1998; 280: 605-13.
12. Vesey MP. Female hormones and vascular disease: an epidemiological overview. Brit J Fam Plan 1980; 6S: 1-12.
13. Stadel BV. Oral contraceptives and cardiovascular disease, part 1. N Engl J Med 1981a; 305: 612-18.
14. Stadel BV. Oral contraceptives and cardiovascular disease, part 2. N Engl J Med 1981b; 305: 672-77.
15. The Coronary Drug Project Research Group. The coronary drug project: findings leading to discontinuation of the 2.5-mg/day estrogen group. JAMA 1973; 226: 652-7.
16. Rubin R. Hormone therapy: doubts grow. USA Today 12 June 2001.
17. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004; 291: 47-53.
18. Viscoli CM, Brass LM, Keman WN et al. A clinical trial of estrogen replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243-9
19. Shumaker SA, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study JAMA 2004; 291: 2947-58.
20. DeMets D, Pocock S, Julian D. The agonising negative trend in monitoring of clinical trials. Lancet 1999; 354: 1983-8.
21. Tyler ET. Eight years' experience with oral contraception and an analysis of use of low-dose norethisterone. Brit Med J 1964; 834-7.
22. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.